Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 13/20 | 0.77 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3278681 | 0.92 | HCAR3 (0.78) | HCAR3MAPTALDH1A1 | |
| SCHEMBL10532495 | 0.91 | HCAR3 (0.65) | HCAR3MAPTALDH1A1KMT2A | |
| SCHEMBL2688335 | 0.87 | HCAR3 (1.00) | HCAR3MAPTALDH1A1KMT2ARAB9A | |
| SCHEMBL31555875 | 0.87 | HCAR3 (0.75) | HCAR3MAPTALDH1A1KMT2APKM | |
| SCHEMBL112074 | 0.87 | KMT2A (0.70) | HCAR3MAPTALDH1A1TSHRTDP1 | |
| SCHEMBL27077338 | 0.87 | HCAR3 (0.75) | HCAR3MAPTALDH1A1KMT2APKM | |
| SCHEMBL6044176 | 0.85 | HCAR3 (1.00) | HCAR3MAPTALDH1A1KMT2ARAB9A | |
| SCHEMBL1306790 | 0.85 | MAPT (0.65) | HCAR3MAPTALDH1A1TSHRTDP1 | |
| SCHEMBL24032 | 0.84 | HCAR3 (1.00) | HCAR3MAPTALDH1A1KMT2A | |
| SCHEMBL10502410 | 0.83 | HCAR3 (0.74) | HCAR3MAPTALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007720-B1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2013-12-25 | — | — | EP | disclosed |
| US-8598168-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-12-03 | — | — | US | disclosed |
| US-7868205-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7868205-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7868205-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2011-01-11 | — | — | US | disclosed |
| US-7700615-B2 | Cell migration inhibiting compositions and methods and compositions for treating cancer | AVOLIX PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| EP-2007720-A1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2008-12-31 | — | — | EP | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | METHYLGENE, INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| WO-2005030704-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030704-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| WO-2003102153-A2 | CELL MIGRATION INHIBITING COMPOSITIONS AND METHODS AND COMPOSITIONS FOR TREATING CANCER | AVOLIX PHARMACEUTICALS (US) | 2003-12-11 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| EP-0487205-B1 | Compositions containing nitroaniline dyes having a carbamide substituent group | BRISTOL MYERS SQUIBB CO (US) | 1996-08-21 | — | — | EP | disclosed |
| EP-0487205-A2 | Compositions containing nitroaniline dyes having a carbamide substituent group | Bristol-Myers Squibb Company (US) | 1992-05-27 | — | — | EP | disclosed |
| US-5042988-A | Compositions containing nitroaniline dyes having a carbamide substituent group | CLAIROL INCORPORATED (US) | 1991-08-27 | — | — | US | disclosed |
| US-4619666-A | Hair dyes containing amino-nitrobenzoic acid or amino-nitrobenzene sulfonic acids as substantive dyes | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1986-10-28 | — | — | US | disclosed |
| EP-0170069-A1 | Hair-dyeing compositions | Henkel Kommanditgesellschaft auf Aktien (DE) | 1986-02-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132459-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | HCAR3 1058/4885MAPT 2110/4885ALDH1A1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.